Histone deacetylase inhibitors (HDIs) have shown promise as candidate radiosensitizers for many types of cancers. However, the mechanisms of action are not well understood, and whether they could sensitize multiple myeloma (MM) to radiation therapy is unclear. In this study, we demonstrate that Suberoylanilide hydroxamic acid (SAHA) at low concentrations has minimal cytotoxic effects, yet can significantly increase radiosensitivity of multiple myeloma (MM) cells. SAHA appears to block RAD51 protein response to ionizing radiation (IR), consistent with an inhibitory effect on the formation of RAD51 focus in irradiated MM cells. These effects of SAHA on RAD51 focus are independent of cell cycle distribution changes. Furthermore, we demonstrate that SAHA selectively inhibits the homology-directed repair (HDR) pathway. The results of this study suggest that SAHA, a recently approved HDI in clinical trials for malignancies, at lower concentrations may act as a radiosensitizer via disruption of the RAD51-dependent HDR pathway.
INTRODUCTION
Multiple myeloma (MM) is an incurable plasma cell malignancy that accounts for about 1% of human cancers [1] . Standard systemic treatment has utilized alkylating agents, anthracyclines, steroids, anti-angiogenics agents, proteosome inhibitors and hemtopoietic cell transplantation. MM cells are also very radiosensitive and locally radiocurable. As a result relatively low doses of radiotherapy have proven to be extremely effective in eradicating focal lesions and in palliating symptoms. Although most myeloma patients initially respond to such approaches, median survival is approximately 4 years due to the refractory and/or relapsed disease [2] .
Particularly challenging are patients with progressive disease after first-line therapies [3] . These patients are often considered for hematopoietic cell transplantation (HCT). Total body irradiation (TBI) containing conditioning HCT regimens are difficult to tolerate given the fact that MM patients are older and the regimens are often combined with chemotherapy agents such as melphalan. Total marrow irradiation (TMI) delivery using large field image guided intensity modulated radiotherapy approaches provides a more targeted form for TBI. This results in a significant reduction in dose to critical normal organs and is better tolerated in HCT patients [4] . Clinical trials have clearly demonstrated the feasibility of combining TMI doses of up to 1200 cGy with concomitant melphalan in patients as old as 66 years of age undergoing HCT [5] [6] . However, further Chen 4 improvements in the therapeutic index of TMI through dose escalation or the addition of chemotherapy agents that add to the toxicities of the conditioning regimen remain challenging. Whether radiotherapy is used to target local regional disease or to multiple regions in the body, there is a clear need for agents and strategies that will increase the radiosensitivity of these cells to RT without significant additional toxicity.
Histone deacetylases (HDAC) and its counterpart, histone acetyltransferases (HAT), modify the chromatin conformation by catalyzing the addition or removal of acetyl group from core histones and nonhistone proteins, and play important roles in many diverse and essential biological processes including intracellular signaling [7] .
HDAC inhibition results in accumulation of acetylated nucleosomal histones and induces differentiation and/or apoptosis in transformed cells. Inhibitors of HDAC, HDIs, have currently emerged as a new class of therapeutic agents for human malignant diseases [8] [9] [10] [11] . The potential of HDIs as radiosensitizer has also been demonstrated in many types of solid tumors in vitro. These HDIs, such as FK228, MS-275 and valproic acid (VPA) can enhance cell cycle arrest, apoptosis, and increase DNA double-strand breaks in irradiated cancer cells [12] [13] [14] [15] . However, HDIs ability to enhance radiosensitivity of MM cells has not been explored, and a more detailed understanding of mechanisms involved is needed.
Suberoylanilide hydroxamic acid (SAHA), an organic hydroxamic acid, is a nonspecific HDI inhibiting the activity of class I, II and IV HDAC enzymes [7] . As an orally administered HDI with a manageable profile of side-effects and preliminary evidence of Chen 5 anti-tumor activity, SAHA was recently approved as single agent therapy for refractory cutaneous T-cell lymphoma. Phase I and II clinical trials combining SAHA with chemotherapy (including trials for advanced & relapsed and/or refractory multiple myeloma), and radiotherapy (for solid tumors) are also ongoing (available from:
www.clinicaltrials.gov) [16] [17] .
In this study, we demonstrate that SAHA at low, minimally cytotoxic doses enhances radiosensitivity of MM cells in vitro, with a novel mechanism involving the inhibition of the homology-directed repair (HDR) pathway of chromosomal breaks.
SAHA significantly inhibits the formation of co-foci of RAD51 with phosphorylated H2A.X (γ-H2A.X), a sign of effective DNA damage repair, in irradiated MM cells. The inhibitory effect of SAHA on the focus formation of RAD51 was not due to changes of S and G 2 /M cell cycle phase distribution, but is associated with the reduced stabilization of RAD51 protein and its chromatin association in response to irradiation. However, unlike other drugs [18] [19] , low dose SAHA could not increase radiosensitization in nonhomologous end joining (NHEJ)-defective cells. In summary, our data suggest that SAHA may serve as a candidate radiosensitizer, which could have clinically important ramifications for MM patients undergoing radiotherapy and chemotherapy. These strategies may also eventually prove to be applicable to other hematologic malignancies. Chen 8 Clonogenic assay. To evaluate radiosensitivity, cells in log phase were seeded at 2×10 5 /mL for 24 hours, and treated with SAHA at the indicated concentrations, or DMSO as control; Irradiation was then delivered 16 hours later. Irradiated cells were maintained in conditioned medium for an additional 3 hours, and then 500 to 5000 cells were suspended in RPMI-1640 medium containing 0.6% SeaPlaque agarose (Lonza, Rockland, ME) and overlaid onto 60-mm dish containing a solidified bottom of 0.6% agarose in RPMI-1640 medium. Once the top layer solidified, 1-2 ml of medium was placed on top to keep the plates moist. Plates were incubated for 2-3 weeks until colonies were visible. The plates were then stained with 0.005% crystal violet for 30 min and destained with PBS. Colonies with greater than 50 cells were counted as surviving colonies and the number of colonies was normalized to that observed for unirradiated controls. Mean inactivation doses were determined by the method of Fertil et al [23] , and the sensitizer enhancement ratio (SER) for HDAC inhibitor treatment was calculated as the ratio of mean inactivation dose control/mean inactivation dose SAHAtreated.
For clonogenic assay with SiRNA, U266B1 cells in log phase were transiently transfected with Ku70 SiRNA or control SiRNA-A. After 24 hours, cells were pretreated with 200 nM SAHA for 16 hours, and irradiated with indicated doses. Cells were then plated 3 hours later after irradiation for colony-formation as described by Matsui et al. [24] . Briefly, 0.5 mL cells (2000 cells/mL) in RPMI 1640 complete medium were added to 2.5 mL 1.2% methylcellulose medium (STEMCELL Technologies Inc., Vancouver, Canada). The mixtures were then plated onto 35-mm Petri dishes and maintained in a 37°C, 5% CO 2 , fully humidified incubator. After 14 days of incubation, Chen 9 colonies consisting >50 cells were directly scored using an inverted microscope and colony formation for each condition calculated in relation to values obtained for untreated control cells.
For clonogenic assay with hamster lung fibroblast and hamster ovary cell lines, cells in log phase were plated for 8 hours, and treated with 200 nM SAHA or DMSO as a control; IR was then delivered 16 hours later. Irradiated cells were maintained in SAHA-containing medium for 7-10 days until colony counting. were then attached to poly-L-lysine-coated glass slides, permeabilized with 0.5% Triton-X100 in PBS for 10 min, and blocked with 0.05% Tween + 2% BSA in PBS for 40 min at room temperature. Cells were then incubated with primary antibodies (anti-RAD51 and anti-phospho-histone H2A.X, or anti-cyclin A antibodies) for 2 hours at 37°C followed by three washes with PBS and a 60-min incubation at 37°C with the corresponding secondary antibodies: Alexa Fluor 594 (Red) and 488 (green) at 1:500 (Invitrogen, Carlsbad, CA). Cells were then washed three times with PBS and mounted with Vectashield mounting medium containing DAPI (Vector Laboratories, Inc., Burlingame, CA). Images were acquired with LSM 510 confocal microscope (Zeiss) with 40X objective and processed by photoshop (Adobe). For quantitative analysis, nuclei were analyzed by eye. At least 100 cells from each experiment were selected at random and were counted to calculate the percentage of cells as "positive" for both RAD51 and γ-H2A.X if they displayed >5 discrete dots in nuclei. Cells containing discrete merged dots Triton insoluble fraction was washed with buffer A (10 mM NaCl, 5 mm MgCl2, 250 mM sucrose, 1 mM EGTA, 10 mM Tris-HCl, pH 7.6) containing protease and phosphatase inhibitors and resuspended in 200 μL of the same buffer. Eighty U/ml of RNase-free DNase I (Roche) were added and the nuclei (Triton insoluble fraction) were incubated for 15 min on ice to digest genomic DNA for easy loading [25] . When applied for western blot assay, 6 μg of total cell lysates and Triton-soluble fractions, and 15 μg of Triton-insoluble fractions were loaded onto SDS-PAGE gel. Chen 12 To verify the changes of protein levels and protein modification, densitometry for western blot signal was performed using the AlphaEase FC software ((AlphaInnotech, CA).
RNase Protection Assay. Total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA). The RNase Protection Assay was performed as previously described [15] . Briefly, 2μg of RNA was incubated with α-32P-UTP labeled singlestranded RNA probes overnight at 56 °C and treated with RNase for 45 min at 30 °C.
The RNA-RNA complexes were resolved by electrophoresis in 6% denaturing polyacrylamide gel and analyzed by autoradiography. Template sets for customdesigned template sets for Double-Strand Break-related genes were purchased from BD Biosciences (San Diego, CA). Chen 16 In exponentially growing populations of unirradiated MM cells, only a small fraction (3%-8%) showed subnuclear RAD51 foci (≥ five foci per nucleus), and no RAD51/γ-H2A.X co-foci were detected. After IR treatment, the percentage of cells with RAD51/γ-H2A.X co-foci achieved maximum levels at 24 hours in U266B1, RPMI8226 and KMS-11 cells, and then decreased at 36 hrs. In MM1.s cells, the percentage for cells with nuclear RAD51/γ-H2A.X co-foci achieved maximum levels at an earlier time point ( 
SAHA-inhibition of RAD51 nuclear focus formation in response to irradiation
is not associated with cell cycle S-G 2 phase changes. Chen 17 Previous studies showed that IR-induced RAD51 nuclear focus formation was cell cycle-regulated [31] [32] . To address whether the inhibitory effects of SAHA on the formation of RAD51/γ-H2A.X co-foci was due to possible cell cycle re-distribution, we determined the kinetics of nuclear accumulation of cyclin A, a marker for cells in S to G 2 /M phase [33] , and its correlation with nuclear RAD51 foci in response to SAHA combined with IR in U266B1 cells.
In unirradiated control and SAHA treated cells, about 8% of cells were positive for RAD51 nuclear foci, and all these cells were also cyclin A nuclear stain positive; an additional ∼12% of the cells were cyclin A-positive alone. After 6 Gy IR, the numbers of cells with cyclin A nuclear staining started increasing within one hour, and continued at very similar rates in the control and SAHA-exposed cell populations, reaching 57.7 ± 4.2% for control and 57.1 
SAHA inhibits homology-directed repair.
Since SAHA treatment caused a reduction in RAD51 levels and focus formation after IR, we hypothesize that SAHA exposure would specifically inhibit the RAD51-dependent, HDR repair pathway for DSBs. We utilized a set of chromosomally integrated reporter assays in sarcoma U2OS cells in which a site-specific DSB is 19 (percentages) in U2OS cells following transient expression of I-SceI were 2.32 ± 0.37, 3.57 ± 0.18 and 4.78 ± 0.80 for HDR, SSA and EJ, respectively. As expected, when cells were exposed to 200 nM of SAHA, HDR was significantly reduced to 1.5 ± 0.27 and SSA was increased to 8.2 ± 0.50, while there was no obvious change to EJ (5.1 ± 0.97) (figure 6A). Furthermore, SiRNA depletion of RAD51 also led to significantly inhibited HDR, and an increase in SSA, with no obvious change to EJ.
In these reporter experiments, SAHA affected HDR in cells not exposed to IR, whereas the effects of SAHA on RAD51 levels in MM cells were only observed after IR treatment. However, the reporter experiments involved an extended exposure to SAHA.
We therefore examined whether SAHA treatment for an extended time would affect HR is thought to afford some backup function for repair of DSB in mammalian cells when the major pathway, non-homologous end joining (NHEJ) is inactivated [35] . It follows that SAHA would be expected to be a more potent radiosensitizer in an NHEJdeficient cell than in a congenic repair proficient one. Contrary to this expectation, 
SAHA modulates RAD51 protein stabilization and reduces the activity of RAD51 in chromatin association in irradiated MM cells.
In an attempt to understand in more detail the mechanisms involved in the SAHAmediated modulation of RAD51 protein levels following IR, we evaluated the effects of SAHA exposure on IR-induced redistribution of RAD51 protein to sites of DNA damage. Cells treated with IR and SAHA were fractionated into a Triton X-100 soluble fraction (TSF) containing free nuclear proteins, and a Triton X-100 insoluble fraction (TISF) containing chromatin-bound proteins [25, 36] . As shown in figure 7A , six hours after irradiation, the amounts of RAD51 in the TSF and TISF increased, concomitant with the increase of total RAD51 protein. However, when cells were exposed to SAHA, the RAD51 in the TISF did not show any obvious increase. Instead, the slightly increased total RAD51 in cells exposed to IR combined with SAHA were confined to the TSF. MG132, a 26S proteasome inhibitor, the repressed RAD51 levels seen previously with SAHA exposure in irradiated cells was restored by ∼50% in all three cell line. A parallel immunofluorescence assay also showed that MG132 treatment restored the cell's ability to form RAD51/γ-H2A.X co-foci at 7 hours after 6 Gy IR in U266B1 cells pre-exposed to SAHA ( figure 7C ). Taken together, these data suggest that SAHA does not influence the gene expression of RAD51, but, at low concentrations, SAHA may reduce protein stability of RAD51 and its redistribution into the nucleus, leading to the inhibition of the chromatin association in response to irradiation.
DISCUSSION
Radiation therapy is a key modality in the treatment of cancer. Although the molecular basis of radiation response is complex and multifactorial, the predominant mechanism by which therapeutic irradiation kills most tumor cells is through clonogenic death. DSBs are regarded as the specific lesions that initiate this lethal response [41] [42] , and the repair of DSBs is then critical in determining radiosensitivity [43] [44] . In In this present study, we demonstrated that treatment with SAHA, at low concentrations that produce minimal cytotoxicity, can radio-sensitize MM cells.
Mechanistic investigations revealed that SAHA exposure disrupts the normal RAD51 responses to IR exposure, and causes inhibition of HDR. We found that the formation of Like other HDIs that have been reported to decrease RAD51 protein and inhibit HDR in response to IR treatment [18, [37] [38] , SAHA exposure lead to the reduction of baseline RAD51 protein levels. However, we present evidence here that SAHA at low concentration can also block the IR-induced increase of RAD51 protein, and furthermore reduce the formation of nuclear RAD51 foci shortly after IR. These effects 
of low dose SAHA on RAD51 dynamics occur before SAHA changes the baseline RAD51 protein levels, indicating SAHA can directly disrupt RAD51 responses to IR. In addition, our data also suggest that SAHA at high concentrations may affect other DNA repair pathways through transcription; however, the potential associated cytotoxicity may limit its clinical applicability.
A pharmacological-genetic epistasis analysis confirmed an inhibitory effect of SAHA on the HR pathway, as the SER for the drug was smaller in an HR-deficient line than for its congenic HR-proficient parental line. A remarkable finding of this work was the absence of increased radiosensitization in NHEJ-deficient cells. This result indicates that the cognate DNA lesions in irradiated cells are somehow not substrates for that repair process, despite its dominant role in DSB rejoining in mammalian cells throughout the cell cycle when SAHA is absent. There is currently little understanding of the manner by which cells "decide" whether a given DSB will repaired via NHEJ versus HR. Perhaps, as a consequence of SAHA acting on the cellular "decision machinery", a subset of DSB becomes inaccessible to repair via NHEJ. Since the alternative HR pathway is inhibited as an independent effect of the drug, however, cell survival is compromised. We are currently investigating this and other possibilities.
We also found that SAHA might enhance the proteasome-mediated degradation of 
Chen 25 [52] . However, we found that MG132 at 500 nM could restore SAHA-inhibited RAD51 protein level and its foci formation after IR. The differences in the effects observed for RAD51 response to IR may be dependent on concentrations of MG132. These data predict that combining SAHA with the proteasome inhibitor bortezomib, may reverse the inhibitory effect of SAHA on HR in response to radiotherapy, but more work needs to be done to confirm this prediction.
The potential of using SAHA as a radiosensitizer in MM treatment through inhibition of HR repair is intriguing, particularly since MM is a radioresponsive disease, radiotherapy plays an important role, and with current advanced technologies in radiotherapy, delivery of dose through allows for the delivery of precisely focused radiation to the major marrow sites where the MM cancer cells most reside. SAHA may also have potential in sensitizing cells to certain chemotherapy agents used in MM, such as Melphalan. Melphalan is an alkylator which is known to be preferentially toxic in cells harboring impaired HR [37] .
We and others have been actively evaluating TMI in MM. Using a TMI approach, radiation sensitizers take on greater importance, since dose deposition can now be controlled and redistributed preferentially to bone and marrow and away from normal organs, resulting in selective radiosensitization of bone and marrow compared to normal tissues. The benefits of a radiosensitization strategy with even modest effects will be further amplified due to selective targeting of dose and radiosensitization to marrow and other user specified target structures. Low dose of SAHA may serve as an ideal 
